Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceteric
- Development stage
- Phase 1
- Lead developer
- Seattle Gummy Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ceteric is a gummy formulation of cetirizine hydrochloride, a second-generation antihistamine developed by Seattle Gummy Company. It is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis, as well as chronic idiopathic urticaria. As a selective H1-receptor antagonist, cetirizine inhibits the interaction of histamine with H1 receptors on effector cells, thereby reducing allergic responses such as sneezing, pruritus, and watery eyes. The gummy delivery system is intended to improve patient compliance and provide a convenient, waterless alternative to traditional tablets or liquid formulations.
- Brand names
- Ceteric
- Other names
- cetirizine HCl Gummycetirizine gummy
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Ceteric.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceteric.